Jpmorgan Chase & CO Gracell Biotechnologies Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$2.43 - $10.04 $34,017 - $140,549	13,999 New	13,999 $140,000
Q4 2023 Feb 12, 2024	BUY	$2.43 - $10.04 $2,821 - $11,656	1,161 Added 9.04%	13,999 $140,000
Q3 2023 Nov 14, 2023	BUY	$2.83 - $4.9 $29,921 - $51,807	10,573 Added 466.8%	12,838 $36,000
Q2 2023 Aug 11, 2023	BUY	$1.45 - $6.07 $89 - $376	62 Added 2.81%	2,265 $8,000
Q1 2023 May 11, 2023	BUY	$1.8 - $2.5 $320 - $445	178 Added 8.79%	2,203 $4,000
Q4 2022 Feb 13, 2023	SELL	$2.08 - $3.96 $2,597 - $4,946	-1,249 Reduced 38.15%	2,025 $5,000
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $884 - $2,188	425 Added 14.92%	3,274 $11,000
Q2 2022 Aug 11, 2022	SELL	$1.95 - $5.5 $6,263 - $17,666	-3,212 Reduced 52.99%	2,849 $16,000
Q1 2022 May 11, 2022	BUY	$1.83 - $5.52 $3,017 - $9,102	1,649 Added 37.38%	6,061 $14,000
Q4 2021 Feb 10, 2022	BUY	$5.65 - $14.9 $24,470 - $64,531	4,331 Added 5346.91%	4,412 $27,000
Q3 2021 Nov 12, 2021	BUY	$9.91 - $14.84 $802 - $1,202	81 New	81 $1,000

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.